Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19666973 | 1.00 | RIPK1 (0.47) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL16756832 | 0.83 | SLC6A2 (0.38) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL25419566 | 0.82 | LMNA (0.48) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL17835547 | 0.82 | LMNA (0.48) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL27094502 | 0.77 | RIPK1 (0.53) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL1520904 | 0.77 | RIPK1 (0.53) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL14758666 | 0.76 | RIPK1 (0.55) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL1779384 | 0.76 | RIPK1 (0.55) | RIPK1LMNAAOC3ALDH1A1KDM4E | |
| SCHEMBL11228716 | 0.75 | RIPK1 (0.53) | RIPK1LMNAAOC3KDM4EL3MBTL1 | |
| SCHEMBL28428630 | 0.72 | KMT2A (0.35) | LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-11-20 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | RIPK1 3578/4885LMNA 4266/4885AOC3 111/4885 |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | NOX1, NOX5, CYBB | RIPK1 3578/4885LMNA 4266/4885AOC3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.